ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

23-valent pneumococcal capsular polysaccharide vaccine

Also written as “PPV23”, “23-valent pneumococcal polysaccharide vaccine” and “Pneumovax™ 23”.

Its studies are mostly in Pneumococcal Infections · Influenza, Human · Diphtheria · Pneumonia, Pneumococcal · Whooping Cough, led by 8 companies.

Drug page23-valent pneumococcal capsular polysaccharide vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 39 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 6, 201416 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only50 open or runningphase 4since Oct 6, 2014Jul 3, 2007none ahead
GlaxoSmithKlineits history only40 open or runningphase 4since Feb 20, 2014Mar 24, 2006none ahead
Sinopharmits history only20 open or runningphase 4since Jan 6, 2021Jan 6, 2021none ahead
Aimei Vacin BioPharm (Zhejiang)its history only11 open or runningphase 3since Sep 13, 2023Sep 13, 2023none ahead
Chongqing Zhifei Biological Productsits history only10 open or runningphase 3since Feb 18, 2020Feb 18, 2020none ahead
Pfizerits history only10 open or runningphase 4since Aug 21, 2006Aug 21, 2006none ahead
Sanofiits history only10 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Sinovac Biotech10 open or runningphase 4since Jul 13, 2022Jul 13, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sinovac Biotech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 13, 2022First study: phase 4 study in Influenza, HumanFirst studyNCT05471531 · 3,000 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

The one study Sinovac Biotech leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05471531Influenza, Human · China4CompletedMar 10, 20223,000

How it is read

Names in the registry

  • “PPV23”, 3 entries
  • “23-valent pneumococcal polysaccharide vaccine”, 3 entries
  • “Pneumovax™ 23”, 3 entries
  • “Pneumo 23”, 2 entries
  • “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.